ASRS 2023: Efficacy/safety of biosimilars ranibizumab-nuna and ranibizumab-eqrn in clinical use
July 30th 2023This study of patients was designed to identify unexpected adverse effects of these new pharmacologic therapies that may not have been observed or anticipated during clinical research trials. The studied drugs were biosimilars to the reference drug ranibizumab.
ASRS 2023: Which topics at the annual meeting did researchers find exciting?
September 5th 2023At the 2023 American Society of Retina Specialists meeting in Seattle, Washington, we asked some of the presenters, "What research here do you find exciting or interesting?" Here's what Diana Do, MD, Shawn Kavoussi, MD, and Durga Borkar, MD, MMCi had to say!
ASRS 2023: Presenters share fascinating research highlights from the 2023 ASRS annual meeting
September 4th 2023At the 2023 American Society of Retina Specialists meeting in Seattle, Washington, we asked some of the presenters, "What research here do you find exciting or interesting?" Here's what Ursula Schmidt-Erfurth, MD, Veena Raiji, MD, and Dante Pieramici, MD had to say!